Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography in Patients With Cytostatic Therapies
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure, Congestive
- Sponsor
- Luzerner Kantonsspital
- Locations
- 1
- Primary Endpoint
- Changes of echocardiographic parameters and changes of electromechanical activation time (EMAT)and development of third heart sound as indicators of congestive heart failure
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
In this study, the investigators sought to determine whether an acoustic cardiographic assessment of heart function is equivalent to Doppler-echocardiography in patients who are treated with cardio-toxic cytostatic agents.
Detailed Description
Patients receiving cardio-toxic cytostatic agents are examined by Doppler-echocardiography and acoustic cardiography before, during, and after the cytostatic treatment. Doppler-echocardiography measures ejection fraction, TDI, speckle tracking, and further parameters. Acoustic cardiography (Audicor, Inovise Medical Inc., Portland, USA) simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. Heart function as assessed by Doppler-echocardiography is then compared to the heart function as assessed by Audicor ECG.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with malignant disease with scheduled anthracycline and trastuzumab therapy
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Changes of echocardiographic parameters and changes of electromechanical activation time (EMAT)and development of third heart sound as indicators of congestive heart failure
Time Frame: Repeated measurements over a year
Secondary Outcomes
- Development of clinically overt congestive heart failure(One year)